Compare Novartis AG (NVS) vs Vipshop Holdings Ltd - ADR (VIPS) Price & Performance

Novartis (NVS) is trading at $137.70, down 13.93% following significant clinical trial setbacks for del-desiran and pelacarsen. The stock shows bearish technical signals with support at $133-$136 and resistance at $140-$143. Fundamentally, the company maintains strong profitability with 74.74% gross margins and 22.5% net income margins, though recent pipeline failures have overshadowed solid financial performance.

While Novartis maintains strong financial fundamentals and reiterated 2025-2030 growth guidance, the recent clinical trial failures create near-term uncertainty. The stock faces pressure from pipeline setbacks but offers value at current levels for long-term investors willing to weather development risks. Analyst consensus remains cautious with 68% hold ratings.

Vipshop Holdings trades at $13.03, down 1.29% with bearish technical signals despite attractive valuation metrics including a P/E of 4.21 and P/S of 0.41. Recent earnings showed mixed results with Q2 2026 missing expectations, while revenue has declined from $112.9B in 2023 to $105.9B in 2025. The company maintains strong profitability with 9.82% net margin and robust cash flow generation.

Analyst consensus remains positive with 54% buy ratings, though near-term headwinds from consumer spending caution and competitive pressures create uncertainty. The stock's deep value proposition is balanced against growth challenges, requiring careful monitoring of Q3 2026 earnings results for directional clarity.